Largest health care biotech companies by market cap
Amgen leads the 24 health care biotech companies ranked by market value, at SEK 2.44T, ahead of Gilead Sciences (SEK 2.13T) and Moderna (SEK 809.7B). Figures as of 18 Nov 2026, 23:55 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSEK 2.44T
- Median
- SEK 108.1B
- Combined market value
- SEK 8.51T
- Countries
- 5
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | Market cap ↓ | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SEK 2.44T | SEK 4,513.77 | 3.07% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | SEK 2.13T | SEK 1,718.30 | 0.75% down | 33% up | ||
| 3 | ModernaMRNA · Health Care | SEK 809.7B | SEK 2,001.09 | 4.84% down | 755% up | ||
| 4 | argenxARGX · Health Care | SEK 601.9B | SEK 9,571.25 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | SEK 377.9B | SEK 2,556.50 | 0.25% up | 49% up | ||
| 6 | Revolution MedicinesRVMD · Health Care | SEK 351.5B | SEK 1,625.16 | 1.76% down | 131% up | ||
| 7 | BioNTechBNTX · Health Care | SEK 209.9B | SEK 846.64 | 1.89% down | 16% down | ||
| 8 | ExelixisEXEL · Health Care | SEK 169.4B | SEK 694.42 | 0.31% down | 63% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | SEK 167.6B | SEK 1,656.07 | 1.84% down | 20% up | ||
| 10 | Bio-TechneTECH · Health Care | SEK 116.2B | SEK 739.77 | 0.17% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | SEK 112.2B | SEK 1,755.82 | 6.47% up | 5% up | ||
| 12 | Halozyme TherapeuticsHALO · Health Care | SEK 111.1B | SEK 974.16 | 0.18% down | 37% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | SEK 105.2B | SEK 1,231.73 | 0.32% down | 87% up | ||
| 14 | QiagenQGEN · Health Care | SEK 104.1B | SEK 503.96 | 0.38% down | 12% up | ||
| 15 | Krystal BiotechKRYS · Health Care | SEK 95B | SEK 3,206.59 | 5.62% up | 46% up | ||
| 16 | VaxcytePCVX · Health Care | SEK 94.2B | SEK 595.07 | 1.48% down | 22% up | ||
| 17 | Twist BioscienceTWST · Health Care | SEK 80.7B | SEK 1,183.12 | 3.88% up | 340% up | ||
| 18 | CG OncologyCGON · Health Care | SEK 72.7B | SEK 813.49 | 1.34% up | 85% up | ||
| 19 | ImmunityBioIBRX · Health Care | SEK 72.5B | SEK 68.13 | 7.03% up | 193% up | ||
| 20 | ImmunovantIMVT · Health Care | SEK 69.8B | SEK 337.29 | 0.12% down | 43% up | ||
| 21 | Kodiak SciencesKOD · Health Care | SEK 65B | SEK 994.60 | 1.04% up | 396% up | ||
| 22 | Scholar Rock HoldingSRRK · Health Care | SEK 59.5B | SEK 488.10 | 6.48% up | 14% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | SEK 46.8B | SEK 289.40 | 0.11% down | 88% up | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | SEK 39.6B | SEK 408.68 | 0.10% up | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 10.1687 SEK).
Questions and answers
Which health care biotech companies rank first by market value?
Amgen (SEK 2.44T), Gilead Sciences (SEK 2.13T) and Moderna (SEK 809.7B) are the top three of the 24 health care biotech companies ranked by market value as of 18 Nov 2026, 23:55 UTC.
How many health care biotech companies are in this ranking?
24 are ranked by market value.
What are these health care biotech companies worth together?
The 24 health care biotech companies ranked by market value have a combined market value of SEK 8.51T as of 18 Nov 2026, 23:55 UTC.
What does ranking by market value measure?
What the stock market values the whole company at: its share price times the number of its shares.
Learn how this ranking works
All markets guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest health care biotech companies by market cap”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care
Underlying data: Yahoo Finance; SEC EDGAR.